Literature DB >> 7206322

Japan's experience in pertussis epidemiology and vaccination in the past thirty years.

K Kanai.   

Abstract

The experience in Japan that pertussis was controlled by the nation-wide regular vaccination and that the reincrease of case notification occurred recently after the decrease of vaccine acceptance rate upholds the view that pertussis vaccine produced under the national control system is fully protective. Though the recent decrease of the vaccine acceptance rate was due to the public reaction to rather imbalaanced arguments concerning the vaccine risk, it is also true that a more potent and less toxic component vaccine is urgently needed at this moment.

Keywords:  Asia; Bacterial And Fungal Diseases--prevention and control; Biology; Causes Of Death; Central Nervous System; Central Nervous System Effects; Child Mortality; Communicable Disease Control; Communicable Diseases; Delivery Of Health Care; Demographic Factors; Developed Countries; Developing Countries; Diseases; Eastern Asia; Government Sponsored Programs; Health; Health Services; Immunity; Immunity, Active; Immunization; Infections; Japan; Literature Review; Medicine; Mortality; National Health Services; Neurologic Effects; Organization And Administration; Physiology; Population; Population Dynamics; Preventive Medicine; Primary Health Care; Program Acceptability; Program Evaluation; Programs; Public Health; Vaccination

Mesh:

Substances:

Year:  1980        PMID: 7206322     DOI: 10.7883/yoken1952.33.107

Source DB:  PubMed          Journal:  Jpn J Med Sci Biol        ISSN: 0021-5112


  9 in total

1.  Antigenic divergence between Bordetella pertussis clinical isolates from Moscow, Russia, and vaccine strains.

Authors:  Olga Borisova; Svetlana Yu Kombarova; Nelli S Zakharova; Marjolein van Gent; Vladimir A Aleshkin; Isabella Mazurova; Frits R Mooi
Journal:  Clin Vaccine Immunol       Date:  2007-01-03

2.  Case-control study on encephalopathy associated with diphtheria-tetanus immunization in Campania, Italy.

Authors:  D Greco
Journal:  Bull World Health Organ       Date:  1985       Impact factor: 9.408

Review 3.  Which strategy for pertussis vaccination today?

Authors:  Dorota Z Girard
Journal:  Paediatr Drugs       Date:  2002       Impact factor: 3.022

Review 4.  No pain no gain? Adjuvant effects of alum and monophosphoryl lipid A in pertussis and HPV vaccines.

Authors:  Thomas C Mitchell; Carolyn R Casella
Journal:  Curr Opin Immunol       Date:  2017-07-17       Impact factor: 7.486

Review 5.  A cellular pertussis vaccine (Infanrix-DTPa; SB-3). A review of its immunogenicity, protective efficacy and tolerability in the prevention of Bordetella pertussis infection.

Authors:  S S Patel; A J Wagstaff
Journal:  Drugs       Date:  1996-08       Impact factor: 9.546

6.  Importance of culture in laboratory diagnosis of Bordetella pertussis infections.

Authors:  P H Gilligan; M C Fisher
Journal:  J Clin Microbiol       Date:  1984-11       Impact factor: 5.948

7.  Genetic diversity and relationships in populations of Bordetella spp.

Authors:  J M Musser; E L Hewlett; M S Peppler; R K Selander
Journal:  J Bacteriol       Date:  1986-04       Impact factor: 3.490

8.  Pertussis in a vaccinated 12-year-old girl.

Authors:  S Sheps
Journal:  Can Med Assoc J       Date:  1984-12-15       Impact factor: 8.262

9.  The impact of a vaccine scare on parental views, trust and information needs: a qualitative study in Sydney, Australia.

Authors:  Catherine King; Julie Leask
Journal:  BMC Public Health       Date:  2017-01-23       Impact factor: 3.295

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.